GO:0033783 25-hydroxycholesterol 7-alpha-hydroxylase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0033783 describes the enzymatic activity that converts 25-hydroxycholesterol to 7alpha,25-dihydroxycholesterol, a cytochrome P450-dependent monooxygenation reaction.
• The activity is classically attributed to CYP7B1, an oxysterol 7alpha-hydroxylase that is distinct from the cholesterol 7alpha-hydroxylase CYP7A1.
• A nonhepatic, interleukin-1beta-stimulated 25-hydroxycholesterol 7alpha-hydroxylase activity was characterized in the immature rat ovary, indicating tissue-specific regulation.
• CYP7B1-mediated degradation of 25-hydroxycholesterol maintains quiescence-activation balance and improves the therapeutic potential of mesenchymal stem cells.
• Loss of hepatic IL22RA1 promotes steatosis by modulating oxysterol metabolism, linking this activity to metabolic liver disease.
• Dysregulation of oxysterol 7alpha-hydroxylation is implicated in breast cancer biology and hereditary spastic paraplegia.
Description
GO:0033783, 25-hydroxycholesterol 7-alpha-hydroxylase activity, is a molecular function that catalyzes the 7alpha-hydroxylation of 25-hydroxycholesterol to produce 7alpha,25-dihydroxycholesterol, and also converts (25R)-cholest-5-ene-3beta,26-diol to (25R)-cholest-5-en-3beta,7alpha,26-triol. This reaction requires molecular oxygen and reducing equivalents from NADPH via a hemoprotein reductase, placing the activity within the cytochrome P450 monooxygenase family. The enzyme responsible has been distinguished from cholesterol 7alpha-hydroxylase (CYP7A1) based on substrate specificity and biochemical behavior in liver microsomes. The activity is now most commonly associated with CYP7B1, also known as oxysterol 7alpha-hydroxylase, which acts on multiple oxysterol substrates.
25-hydroxycholesterol 7-alpha-hydroxylase activity At A Glance
| GO ID | GO:0033783 |
|---|---|
| GO term | 25-hydroxycholesterol 7-alpha-hydroxylase activity |
| Ontology | molecular_function |
| Synonym | 25-hydroxycholesterol 7alpha-monooxygenase activity; cholest-5-ene-3beta,25-diol,NADPH:oxygen oxidoreductase (7alpha-hydroxylating) activity; CYP7B1; CYP7B1 oxysterol 7alpha-hydroxylase activity |
| Major function | 7alpha-hydroxylation of 25-hydroxycholesterol and related oxysterols |
| Cofactors | O2 and reduced NADPH--hemoprotein reductase |
| Products | 7alpha,25-dihydroxycholesterol; (25R)-cholest-5-en-3beta,7alpha,26-triol |
| Representative enzyme | CYP7B1 (oxysterol 7alpha-hydroxylase) |
| Tissue context | Liver, ovary, and other tissues; inducible by interleukin-1beta in immature rat ovary |
What Is GO:0033783?
In simple terms, GO:0033783 is the enzyme activity that adds a hydroxyl group at the 7alpha position of 25-hydroxycholesterol. According to the QuickGO definition, it catalyzes the reaction: 25-hydroxycholesterol + O2 + reduced [NADPH--hemoprotein reductase] = 7alpha,25-dihydroxycholesterol + H+ + H2O + oxidized [NADPH--hemoprotein reductase]. It also converts (25R)-cholest-5-ene-3beta,26-diol to (25R)-cholest-5-en-3beta,7alpha,26-triol. This is a cytochrome P450-type monooxygenation that consumes oxygen and reducing equivalents and yields a hydroxylated oxysterol product.
Why Is 25-hydroxycholesterol 7-alpha-hydroxylase activity Important in Cell Biology?
GO:0033783 is important because it controls the steady-state levels of 25-hydroxycholesterol and related oxysterols, which are bioactive lipids with roles in immunity, metabolism, and cell-fate decisions. The activity is a key node in oxysterol catabolism, and its dysregulation has been linked to hepatic steatosis, metabolic-associated fatty liver disease, breast cancer biology, and hereditary spastic paraplegia. Because the enzyme can be studied with genetic and biochemical tools, it is a tractable target for understanding oxysterol signaling and for developing experimental models of disease.
• Controls catabolism of 25-hydroxycholesterol, a bioactive oxysterol.
• Distinct from CYP7A1-mediated cholesterol 7alpha-hydroxylation, defining a separate oxysterol pathway.
• Regulated by inflammatory signals such as interleukin-1beta in nonhepatic tissues.
• Modulates hepatic steatosis and metabolic-associated fatty liver disease in mouse models.
• Maintains quiescence-activation balance in mesenchymal stem cells.
• Implicated in breast cancer through (25R)-26-hydroxycholesterol biology.
• Linked to hereditary spastic paraplegia in genetic studies.
• Provides a biochemical readout for oxysterol pathway flux in liver and steroidogenic tissues.
Molecular Mechanism of 25-hydroxycholesterol 7-alpha-hydroxylase activity
Substrate recognition and binding
In simple terms: The enzyme first grabs the oxysterol substrate and positions it for modification.
The activity acts on 25-hydroxycholesterol and also on (25R)-cholest-5-ene-3beta,26-diol, indicating that the enzyme recognizes sterol substrates with a hydroxyl group on the side chain. Early biochemical work in liver microsomes showed that the 7alpha-hydroxylation of 25-hydroxycholesterol is catalyzed by an enzyme distinct from cholesterol 7alpha-hydroxylase, based on differential substrate specificity and behavior. This substrate preference is a defining feature of GO:0033783 and distinguishes it from CYP7A1-mediated cholesterol 7alpha-hydroxylation.
Catalytic monooxygenation
In simple terms: The enzyme uses oxygen and reducing power to insert a hydroxyl group at the 7alpha position.
The reaction consumes O2 and reduced [NADPH--hemoprotein reductase] and produces 7alpha,25-dihydroxycholesterol plus H+, H2O, and oxidized [NADPH--hemoprotein reductase]. This is characteristic of cytochrome P450 monooxygenation, in which the heme iron activates molecular oxygen and transfers one oxygen atom to the substrate. The same activity can perform a second 7alpha-hydroxylation on (25R)-cholest-5-ene-3beta,26-diol to yield (25R)-cholest-5-en-3beta,7alpha,26-triol.
Cofactor and redox coupling
In simple terms: A partner reductase supplies electrons so the reaction can proceed.
The definition specifies reduced [NADPH--hemoprotein reductase] as the electron donor, which is oxidized during turnover. This coupling places the activity within the NADPH-dependent cytochrome P450 redox system, where the reductase shuttles electrons from NADPH to the P450 heme center. The requirement for molecular oxygen and a reduced hemoprotein reductase is a core biochemical feature of GO:0033783.
Tissue-specific and inducible regulation
In simple terms: The same activity can be turned up or down depending on the tissue and signals.
A nonhepatic 25-hydroxycholesterol 7alpha-hydroxylase activity was characterized in the immature rat ovary and was markedly stimulated by interleukin-1beta, showing that the activity is not restricted to liver and can be induced by inflammatory cytokines. In liver, the activity contributes to oxysterol metabolism, and hepatic IL22RA1 deficiency alters oxysterol levels and promotes steatosis, linking the activity to metabolic regulation. CYP7B1-mediated 25-hydroxycholesterol degradation also maintains quiescence-activation balance in mesenchymal stem cells, demonstrating cell-context-dependent control.
Physiological consequences of product formation
In simple terms: The products of the reaction influence cell behavior and disease processes.
The 7alpha-hydroxylated oxysterol products are downstream metabolites that can affect lipid signaling and cellular responses. In mouse models, oxysterol 7-alpha hydroxylase (CYP7B1) attenuates metabolic-associated fatty liver disease at thermoneutrality, indicating that the activity influences whole-body metabolic phenotypes. In mesenchymal stem cells, CYP7B1-mediated 25-hydroxycholesterol degradation supports the balance between quiescence and activation and improves therapeutic potential.
Key Genes Involved in GO:0033783 25-hydroxycholesterol 7-alpha-hydroxylase activity
The table below lists genes and proteins directly implicated in GO:0033783 or in the oxysterol pathways that intersect with this activity, based on the verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| CYP7B1 | Oxysterol 7alpha-hydroxylase that catalyzes 7alpha-hydroxylation of 25-hydroxycholesterol | Core enzyme for GO:0033783; studied in liver, stem cells, and metabolic disease |
| CYP7A1 | Cholesterol 7alpha-hydroxylase; can exhibit oxysterol 7alpha-hydroxylase activity in vitro | Used to distinguish the 25-hydroxycholesterol 7alpha-hydroxylase activity from classical bile acid synthesis |
| IL22RA1 | Hepatic interleukin-22 receptor subunit; modulates oxysterol levels | Hepatic deficiency promotes steatosis via oxysterol changes |
| IL1B | Interleukin-1beta; stimulates nonhepatic 25-hydroxycholesterol 7alpha-hydroxylase activity | Cytokine regulation of the activity in ovary |
| CH25H | 25-hydroxycholesterol synthase; produces the substrate for GO:0033783 | Upstream of the activity; relevant to oxysterol flux |
| NR1H2 | Liver X receptor beta; oxysterol sensor | Downstream oxysterol signaling context |
| NR1H3 | Liver X receptor alpha; oxysterol sensor | Downstream oxysterol signaling context |
| SCP2 | Sterol carrier protein 2; sterol trafficking | Supports oxysterol metabolism studies |
| ABCA1 | Cholesterol efflux transporter | Oxysterol-responsive lipid handling |
| ABCG1 | Cholesterol efflux transporter | Oxysterol-responsive lipid handling |
| SREBF1 | Lipogenic transcription factor | Linked to steatosis phenotypes in oxysterol models |
| SREBF2 | Cholesterol biosynthesis transcription factor | Feedback regulation of sterol pathways |
| CYP27A1 | Sterol 27-hydroxylase; produces 27-hydroxycholesterol | Related oxysterol pathway |
| CYP46A1 | Cholesterol 24-hydroxylase; brain oxysterol pathway | Comparative oxysterol enzyme |
| SPG5 | Spastic paraplegia 5 locus; associated with CYP7B1 mutations | Hereditary spastic paraplegia genetics |
| BSEP | Bile salt export pump; bile acid transport | Liver bile acid homeostasis context |
| FXR | Farnesoid X receptor; bile acid sensor | Feedback regulation of bile acid and oxysterol pathways |
| RORC | RAR-related orphan receptor C; binds oxysterols | Downstream oxysterol signaling |
How Is 25-hydroxycholesterol 7-alpha-hydroxylase activity Regulated?
The activity is regulated at multiple levels. In the immature rat ovary, a nonhepatic 25-hydroxycholesterol 7alpha-hydroxylase is markedly stimulated by interleukin-1beta, demonstrating cytokine-inducible regulation. In liver, hepatic IL22RA1 deficiency alters oxysterol levels and promotes steatosis, indicating that inflammatory and metabolic signals can influence the pathway. CYP7B1-mediated 25-hydroxycholesterol degradation maintains quiescence-activation balance in mesenchymal stem cells, showing that the activity is also controlled in a cell-state-dependent manner. At thermoneutrality, oxysterol 7-alpha hydroxylase (CYP7B1) attenuates metabolic-associated fatty liver disease in mice, suggesting that environmental temperature and metabolic context modulate the pathway.
25-hydroxycholesterol 7-alpha-hydroxylase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| CYP7B1 | Hereditary spastic paraplegia; oxysterol metabolism | Knockout or point-mutation cell models in neuronal lines |
| IL22RA1 | Hepatic steatosis; oxysterol modulation | Liver-specific knockout or overexpression models |
| CYP7B1 | Metabolic-associated fatty liver disease | Thermoneutral mouse models and hepatocyte knockouts |
| CYP7B1 | Mesenchymal stem cell quiescence-activation balance | Stem cell knockout and overexpression models |
| CYP7A1 | Bile acid synthesis; oxysterol 7alpha-hydroxylase activity in vitro | Biochemical assays and knockout hepatocytes |
Metabolic liver disease and steatosis
Hepatic IL22RA1 deficiency promotes hepatic steatosis by modulating oxysterol levels in the liver, linking GO:0033783-related oxysterol metabolism to fatty liver disease. In mice, oxysterol 7-alpha hydroxylase (CYP7B1) attenuates metabolic-associated fatty liver disease at thermoneutrality, indicating that the activity can protect against steatosis under specific metabolic conditions. These findings suggest that the 7alpha-hydroxylation of 25-hydroxycholesterol is part of a hepatic oxysterol network that influences lipid accumulation.
Breast cancer and oxysterol signaling
Breast cancer has been linked to (25R)-26-hydroxycholesterol biology, an oxysterol that intersects with the same 7alpha-hydroxylation pathway. Because GO:0033783 acts on 25-hydroxycholesterol and related side-chain hydroxylated sterols, changes in this activity could alter the balance of pro- and anti-tumorigenic oxysterols. The precise role of the activity in breast cancer remains an active area of research, but the association highlights its potential relevance to cancer biology.
Hereditary spastic paraplegia
The genetic landscape of hereditary spastic paraplegia in Greece includes genes involved in oxysterol metabolism, and CYP7B1 is a known spastic paraplegia gene. Since CYP7B1 carries the oxysterol 7alpha-hydroxylase activity described by GO:0033783, mutations affecting this activity can contribute to neurodegenerative phenotypes. This connection places the activity within the broader context of inherited axonopathies.
Stem cell quiescence and regenerative medicine
CYP7B1-mediated 25-hydroxycholesterol degradation maintains quiescence-activation balance and improves the therapeutic potential of mesenchymal stem cells. This indicates that GO:0033783 can influence stem cell fate decisions and may be relevant to regenerative medicine applications. Modulating the activity could therefore be a strategy to enhance stem cell-based therapies.
From 25-hydroxycholesterol 7-alpha-hydroxylase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of CYP7B1 alter 25-hydroxycholesterol levels? | CYP7B1 knockout cell line or mouse model |
| Does a specific point mutation abolish 7alpha-hydroxylase activity? | Point-mutation knock-in of CYP7B1 catalytic residues |
| Can tagged CYP7B1 be used to monitor subcellular localization? | Tagged knock-in of CYP7B1 |
| Does overexpression of CYP7B1 reduce 25-hydroxycholesterol? | CYP7B1 overexpression cell model |
| How does IL22RA1 deficiency affect oxysterol flux? | IL22RA1 knockout hepatocytes |
| Does interleukin-1beta induce the activity in nonhepatic cells? | Ovary-derived cell models treated with IL1B |
How to Study the 25-hydroxycholesterol 7-alpha-hydroxylase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Microsomal enzyme assay | Conversion of 25-hydroxycholesterol to 7alpha,25-dihydroxycholesterol | Distinguishing oxysterol 7alpha-hydroxylase from CYP7A1 |
| LC-MS/MS oxysterol profiling | Levels of 25-hydroxycholesterol and hydroxylated products | Liver and stem cell oxysterol flux |
| CYP7B1 knockout | Loss of enzyme activity and downstream effects | Metabolic liver disease and stem cell studies |
| CYP7B1 overexpression | Increased 25-hydroxycholesterol degradation | Stem cell quiescence-activation balance |
| IL1B stimulation assay | Induction of nonhepatic 7alpha-hydroxylase activity | Ovary-derived cell models |
| RNA-seq | Transcriptional changes after pathway manipulation | Pathway and disease mechanism discovery |
| Tagged knock-in imaging | Subcellular localization of CYP7B1 | Protein trafficking studies |
| Point-mutation knock-in | Catalytic residue requirement | Structure-function analysis |
Biochemical enzyme assays
The activity can be measured in liver microsomes or recombinant systems by incubating with 25-hydroxycholesterol and monitoring the formation of 7alpha,25-dihydroxycholesterol. These assays use NADPH and a hemoprotein reductase to supply reducing equivalents, as specified in the GO definition. Such biochemical approaches were essential to distinguish the 25-hydroxycholesterol 7alpha-hydroxylase from cholesterol 7alpha-hydroxylase.
Mass spectrometry-based oxysterol profiling
Mass spectrometry can quantify 25-hydroxycholesterol and its 7alpha-hydroxylated products in cells and tissues, providing a direct readout of GO:0033783 flux. This approach has been used to show that hepatic IL22RA1 deficiency modulates oxysterol levels in the liver. It is also applicable to stem cell models where CYP7B1-mediated degradation of 25-hydroxycholesterol is studied.
Genetic knockout and knockdown
Knockout or knockdown of CYP7B1 in cell lines and mouse models allows researchers to test the contribution of GO:0033783 to oxysterol metabolism and disease phenotypes. For example, CYP7B1 attenuation of metabolic-associated fatty liver disease was demonstrated in mouse models at thermoneutrality. Stem cell studies have used CYP7B1 manipulation to link the activity to quiescence-activation balance.
Transcriptomic and pathway analysis
RNA sequencing and pathway analysis can reveal how loss or gain of the activity affects downstream gene expression programs, including lipid metabolism and inflammatory pathways. Such analyses help connect GO:0033783 to broader biological processes such as steatosis and stem cell fate.
How CRISPR Can Be Used to Study GO:0033783 25-hydroxycholesterol 7-alpha-hydroxylase activity
Knockout
CRISPR knockout of CYP7B1 can eliminate GO:0033783 activity, allowing researchers to measure consequent changes in 25-hydroxycholesterol and 7alpha,25-dihydroxycholesterol levels. Such models are useful for studying metabolic-associated fatty liver disease and stem cell quiescence-activation balance. Knockout of upstream regulators such as IL22RA1 can also reveal how oxysterol flux is modulated in liver.
Point Mutation
Point-mutation knock-in can be used to test which residues are required for 7alpha-hydroxylation of 25-hydroxycholesterol, based on the cytochrome P450 mechanism. Such models help distinguish catalytic residues from substrate-binding determinants. They are particularly valuable for linking genetic variants to loss or gain of enzyme activity.
Knock-in
Tagged knock-in of CYP7B1 enables visualization and immunoprecipitation of the endogenous enzyme, supporting studies of its localization and interaction partners. Knock-in of disease-associated variants can model hereditary spastic paraplegia and other disorders linked to oxysterol metabolism. These models preserve endogenous regulatory context better than overexpression systems.
Overexpression
Overexpression of CYP7B1 increases the 7alpha-hydroxylation of 25-hydroxycholesterol and can reduce substrate levels, as shown in mesenchymal stem cell studies. This approach is useful for testing whether enhanced activity is protective in metabolic or inflammatory contexts. Overexpression models also help establish causality between the activity and downstream phenotypes.
How EDITGENE Supports 25-hydroxycholesterol 7-alpha-hydroxylase activity Research
Researchers studying 25-hydroxycholesterol 7-alpha-hydroxylase activity-related genes often need to determine whether a candidate gene is causally involved in oxysterol metabolism, metabolic liver disease, stem cell fate, or neurodegeneration. Establishing causality requires precise genetic models that can knock out, mutate, tag, or overexpress the relevant enzyme in a controlled cellular context. EDITGENE provides these models to accelerate hypothesis testing and translational research.
Contact EDITGENE today to design your custom CRISPR model for 25-hydroxycholesterol 7-alpha-hydroxylase activity research.
Frequently Asked Questions About 25-hydroxycholesterol 7-alpha-hydroxylase activity
What is 25-hydroxycholesterol 7-alpha-hydroxylase activity?
It is the enzyme activity defined by GO:0033783 that converts 25-hydroxycholesterol to 7alpha,25-dihydroxycholesterol using oxygen and reduced NADPH--hemoprotein reductase.
What gene encodes 25-hydroxycholesterol 7-alpha-hydroxylase activity?
The activity is most commonly associated with CYP7B1, also known as oxysterol 7alpha-hydroxylase, which is distinct from cholesterol 7alpha-hydroxylase CYP7A1.
What is the difference between CYP7A1 and CYP7B1?
CYP7A1 is the classical cholesterol 7alpha-hydroxylase, while the 25-hydroxycholesterol 7alpha-hydroxylase activity is catalyzed by a different enzyme, now attributed to CYP7B1.
What reaction does GO:0033783 catalyze?
It catalyzes 25-hydroxycholesterol + O2 + reduced [NADPH--hemoprotein reductase] = 7alpha,25-dihydroxycholesterol + H+ + H2O + oxidized [NADPH--hemoprotein reductase], and also converts (25R)-cholest-5-ene-3beta,26-diol to (25R)-cholest-5-en-3beta,7alpha,26-triol.
Is 25-hydroxycholesterol 7-alpha-hydroxylase activity regulated by inflammation?
Yes, a nonhepatic form of the activity in the immature rat ovary is markedly stimulated by interleukin-1beta.
How is 25-hydroxycholesterol 7-alpha-hydroxylase activity linked to liver disease?
Hepatic IL22RA1 deficiency promotes steatosis by modulating oxysterols, and CYP7B1 attenuates metabolic-associated fatty liver disease in mice at thermoneutrality.
What diseases are associated with CYP7B1 and this activity?
CYP7B1 is associated with hereditary spastic paraplegia, and oxysterol pathway changes have been linked to breast cancer and metabolic liver disease.
How can I measure 25-hydroxycholesterol 7-alpha-hydroxylase activity?
Biochemical microsomal assays and mass spectrometry-based oxysterol profiling can measure the conversion of 25-hydroxycholesterol to its 7alpha-hydroxylated product.
Does this activity affect stem cells?
Yes, CYP7B1-mediated 25-hydroxycholesterol degradation maintains quiescence-activation balance and improves the therapeutic potential of mesenchymal stem cells.
What CRISPR models are available for studying GO:0033783?
Knockout, point-mutation knock-in, tagged knock-in, and overexpression models of CYP7B1 and related genes can be generated to study the activity and its downstream effects.
Conclusion
GO:0033783, 25-hydroxycholesterol 7-alpha-hydroxylase activity, is a cytochrome P450-dependent monooxygenation that converts 25-hydroxycholesterol to 7alpha,25-dihydroxycholesterol and acts on related side-chain hydroxylated sterols. The activity is most commonly attributed to CYP7B1 and is distinct from classical cholesterol 7alpha-hydroxylase, with important roles in liver metabolism, stem cell fate, and disease. Continued research using precise genetic models will clarify how this activity contributes to metabolic, neoplastic, and neurodegenerative conditions.
References
- 1. Huang Y et al.. 2025. Hepatic IL22RA1 deficiency promotes hepatic steatosis by modulating oxysterol in the liver.. Hepatology 81(5):1564-1582 PMID: 38985984
- 2. Norlin M et al.. 2000. Oxysterol 7 alpha-hydroxylase activity by cholesterol 7 alpha-hydroxylase (CYP7A).. J Biol Chem 275(44):34046-53 PMID: 10882719
- 3. Javitt NB. 2015. Breast cancer and (25R)-26-hydroxycholesterol.. Steroids 104:61-4 PMID: 26299212
- 4. Toll A et al.. 1994. 7 alpha hydroxylation of 25-hydroxycholesterol in liver microsomes. Evidence that the enzyme involved is different from cholesterol 7 alpha-hydroxylase.. Eur J Biochem 224(2):309-16 PMID: 7925343
- 5. Koutsis G et al.. 2026. The Genetic Landscape of Hereditary Spastic Paraplegia in Greece.. Clin Genet 109(5):837-846 PMID: 41277402
- 6. Payne DW et al.. 1995. A novel nonhepatic hydroxycholesterol 7 alpha-hydroxylase that is markedly stimulated by interleukin-1 beta. Characterization in the immature rat ovary.. J Biol Chem 270(32):18888-96 PMID: 7642545
- 7. Evangelakos I et al.. 2021. Oxysterol 7-α Hydroxylase (CYP7B1) Attenuates Metabolic-Associated Fatty Liver Disease in Mice at Thermoneutrality.. Cells 10(10) PMID: 34685636
- 8. Zhang Z et al.. 2024. CYP7B1-mediated 25-hydroxycholesterol degradation maintains quiescence-activation balance and improves therapeutic potential of mesenchymal stem cells.. Cell Chem Biol 31(7):1277-1289.e7 PMID: 38382532
